Aclaris Therapeutics prices $50 million stock and pre-funded warrant offering
ACRS•Aclaris Therapeutics priced an offering expected to raise approximately $50 million in gross proceeds before fees and expenses. It includes 7,785,714 shares at $3.50 each and warrants for 6.5 million shares at $3.49999 each; closing is expected October 28, 2026.
1. Offering details
Aclaris Therapeutics priced an underwritten offering expected to raise approximately $50 million in gross proceeds before fees and expenses. The offering comprises 7,785,714 common shares at $3.50 per share and pre-funded warrants to purchase 6.5 million shares at $3.49999 per share in lieu of shares for certain investors. Closing is expected on October 28, 2026, subject to customary conditions.
